Karyopharm announces publication of xpovio® (selinexor) phase 3 boston study results in the lancet

Newton, mass., nov. 12, 2020 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the results of the phase 3 boston (bortezomib, selinexor and dexamethasone) study evaluating xpovio...

KPTI Ratings Summary

KPTI Quant Ranking